Evidence map›Paper›PMID 38645165›Full record

ArticleResearch square2024

Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers.

David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy N Courtney, Azlann B Arnett, Julien Fleurence, Ramy Sweidan, Thao Wang, Huimin Zhang and 21 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 16 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 4 institutions in 1 country.

David SteffinTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Nisha GhatwaiTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Antonino MontalbanoTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Purva RathiTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Amy N CourtneyTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Azlann B ArnettCenter for Advanced Innate Cell Therapy, Baylor College of Medicine, Houston, Texas.
Julien FleurenceTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Ramy SweidanDepartment of Immunology and Microbiology, Baylor College of Medicine, Texas.
Thao WangDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-1957-7160
Huimin ZhangDepartment of Immunology and Microbiology, Baylor College of Medicine, Texas.
Prakash MasandDepartment of Radiology, Baylor College of Medicine, Houston, Texas.
John M MarisDepartment of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-8088-7929
Daniel MartinezPathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Jennifer PogorilerPathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Navin VaradarajanWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas.ORCID 0000-0001-7524-8228
Sachin G ThakkarDepartment of Immunology and Microbiology, Baylor College of Medicine, Texas.
Deborah LyonDepartment of Immunology and Microbiology, Baylor College of Medicine, Texas.
Natasha LaptevaDepartment of Immunology and Microbiology, Baylor College of Medicine, Texas.
Zhuyong MeiDepartment of Immunology and Microbiology, Baylor College of Medicine, Texas.
Kalyani PatelDepartment of Pathology, Baylor College of Medicine, Houston, Texas.
Dolores Lopez-TerradaDepartment of Pathology, Baylor College of Medicine, Houston, Texas.
Carlos RamosDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Premal LullaDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Tannaz ArmaghanyDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Bambi J GrilleyTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Gianpietro DottiLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Leonid S MetelitsaTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Helen E HeslopDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-7049-7698
Malcolm K BrennerDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Pavel SumazinTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Andras HeczeyTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-4263-9115
Baylor College of Medicine · USChildren's Hospital of Philadelphia · USUniversity of Houston · USUniversity of North Carolina at Chapel Hill · US

Funding

Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$8.7M
IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumorsR01CA258866 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI Andras A. Heczey · 2022 to 2026
$3.1M
The Clinical Translational Research Certificate of Added Qualification ProgramT32GM136554 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI Melissa Suter, IGNATIA B VAN DEN VEYVER · 2020 to 2026
$3.0M
MusIC: A multi-scale technology for integrating dynamic cellular function and molecular profilesR01GM143243 · NIGMS · UNIVERSITY OF HOUSTON · PI VARADARAJAN, NAVIN · 2021 to 2024
$1.8M
PURPOSE OF THE NGVB CONTRACT IS TO CONTINUE SUPPORTING GENE THERAPY RESEARCH.75N92019D00018 · OD · INDIANA UNIVERSITY INDIANAPOLIS · 2019 to 2023
$1.7M
Discovery of chemoresistant tumor subclones in pediatric liver cancersR21CA286257 · NCI · BAYLOR COLLEGE OF MEDICINE · PI SUMAZIN, PAVEL · 2024 to 2025
$413k
REGULATION OF THE BIOSYNTHESIS OF THE OPIOID PEPTIDES AND OTHER NEUROPEPTIDESZ01HL000018 · NHLBI · HEART, LUNG, AND BLOOD INSTITUTE · PI SABOL, S L · 1985 to 1992
–
NCI NIH HHS R01 CA258866NCI NIH HHS R21 CA286257NCI NIH HHS R35 CA220500NHLBI NIH HHS 75N92019D00018NIGMS NIH HHS R01 GM143243NIGMS NIH HHS T32 GM136554
6 · The paper itself

Abstract

Interleukin-15 (IL15) promotes the survival of T lymphocytes and enhances the antitumor properties of CAR T cells in preclinical models of solid neoplasms in which CAR T cells have limited efficacy

Identifiers

PMID38645165
PMCPMC11030543
OpenAlexW4393899910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.